Summary
PhosPrint's D-LIB platform technology is based on a compact and automated laser bioprinter and protocols for high-speed and high-precision in-vivo printing of tissues with autologous human body characteristics.
The bioprinter relies on the Laser Induced Forward Transfer (LIFT) technique to accomplish highly accurate and cost-effective printing of tissues. The bioprinter system is associated with protocols for cell isolation from autologous biopsies, cell expansion in-vitro, and cell printing in-vivo.
This is a truly new approach that allows for real-time tissue engineering/repair in complex medical conditions. D-LIB capabilities will enable the introduction of a laser bioprinting technology in surgery operations, starting with enterocystoplasty/augmentation in cystectomy bladder cancer patients as the selected go-to-market application.
The bioprinter relies on the Laser Induced Forward Transfer (LIFT) technique to accomplish highly accurate and cost-effective printing of tissues. The bioprinter system is associated with protocols for cell isolation from autologous biopsies, cell expansion in-vitro, and cell printing in-vivo.
This is a truly new approach that allows for real-time tissue engineering/repair in complex medical conditions. D-LIB capabilities will enable the introduction of a laser bioprinting technology in surgery operations, starting with enterocystoplasty/augmentation in cystectomy bladder cancer patients as the selected go-to-market application.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190195672 |
| Start date: | 01-05-2023 |
| End date: | 30-04-2025 |
| Total budget - Public funding: | 2 857 944,63 Euro - 2 000 560,00 Euro |
Cordis data
Original description
PhosPrint's D-LIB platform technology is based on a compact and automated laser bioprinter and protocols for high-speed and high-precision in-vivo printing of tissues with autologous human body characteristics.The bioprinter relies on the Laser Induced Forward Transfer (LIFT) technique to accomplish highly accurate and cost-effective printing of tissues. The bioprinter system is associated with protocols for cell isolation from autologous biopsies, cell expansion in-vitro, and cell printing in-vivo.
This is a truly new approach that allows for real-time tissue engineering/repair in complex medical conditions. D-LIB capabilities will enable the introduction of a laser bioprinting technology in surgery operations, starting with enterocystoplasty/augmentation in cystectomy bladder cancer patients as the selected go-to-market application.
Status
SIGNEDCall topic
HORIZON-EIC-2022-ACCELERATORCHALLENGES-01Update Date
31-07-2023
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
